---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-054219"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2026-05-11T12:40:53+00:00"
generated_at: "2026-05-11T18:35:13.425399+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Adial Pharma Q1 net loss $2M; cash $4.6M; FDA policy shift may aid AD04 path

## Summary
- Cash $4.6M as of Mar 31, 2026, down from $5.9M at Dec 31, 2025; runway into H2 2026.
- Net loss $2.0M vs $2.2M YoY; R&D expenses down 42% to $433K; G&A up 3% to $1.6M.
- FDA signals possible single pivotal trial for AD04; bipartisan AUD legislation introduced.
- Established collaboration framework with Molteni Farmaceutici for European commercial pathway.
- International patent application published; if granted, AD04 protection extended to 2045.

## SEC filing metadata
- accession: 0001213900-26-054219
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2026-05-11T12:40:53+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390026054219/0001213900-26-054219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390026054219/ea0289947-8k_adialpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-054219
- JSON: https://secwatch.observer/filing/0001213900-26-054219.json
- Plain text: https://secwatch.observer/filing/0001213900-26-054219.txt

## Key facts
- Earnings Releases
  ADIAL PHARMACEUTICALS, INC. reported first quarter ended March 31, 2026 results: net income $2.0 million.
  - Period: first quarter ended March 31, 2026
  - Net income: $2.0 million
  - Result: reported results
  source text: Net Loss was $2.0 million for the three months ended March 31, 2026, compared to a net loss of $2.2 million for the three months ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390026054219/0001213900-26-054219-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.